SCHOLAR ROCK HOLDING CORPORATION Increase (Decrease) in Contract with Customer, Liability
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Increase (Decrease) in Contract with Customer, Liability of -$33.19 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-03-19
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2022-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2022-06-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2022-03-31 was -$33.19M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for fiscal 2022 was -$33.19M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for fiscal 2021 was -$18.82M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for fiscal 2020 was -$15.40M, a 441.68% decline from fiscal 2019.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in contract with customer, liability for fiscal 2019 was $4.51M, a 92.83% decline from fiscal 2018.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | -$33.19M 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | -$33.19M 10-Q · filed 2023-11-07 | -$37.24M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$33.19M 10-Q · filed 2023-08-09 | -$37.24M derived: sum of 3 quarters · filed 2023-08-09 | -$42.71M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$33.19M 10-Q · filed 2023-05-09 | -$37.24M derived: sum of 2 quarters · filed 2023-05-09 | -$42.71M derived: sum of 3 quarters · filed 2023-05-09 | -$47.30M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$9.51M derived: sum of 2 quarters · filed 2023-03-07 | -$14.11M derived: sum of 3 quarters · filed 2023-03-07 | -$18.82M 10-K · filed 2023-03-07 |
| 2021-09-30 | -$5.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$10.06M derived: sum of 2 quarters · filed 2022-11-14 | -$14.77M 10-Q · filed 2022-11-14 | -$18.20M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$4.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$9.30M 10-Q · filed 2022-08-08 | -$12.74M derived: sum of 3 quarters · filed 2022-08-08 | -$15.78M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$4.71M 10-Q · filed 2022-05-16 | -$8.14M derived: sum of 2 quarters · filed 2022-05-16 | -$11.18M derived: sum of 3 quarters · filed 2022-05-16 | -$15.08M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$6.47M derived: sum of 2 quarters · filed 2022-03-07 | -$10.37M derived: sum of 3 quarters · filed 2022-03-07 | -$15.40M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$6.94M derived: sum of 2 quarters · filed 2021-11-09 | -$11.97M 10-Q · filed 2021-11-09 | $5.46M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$8.93M 10-Q · filed 2021-08-10 | $8.50M derived: sum of 3 quarters · filed 2021-08-10 | $3.72M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$5.03M 10-Q · filed 2021-05-13 | $12.40M derived: sum of 2 quarters · filed 2021-05-13 | $7.62M derived: sum of 3 quarters · filed 2021-05-13 | $2.58M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $17.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $12.65M derived: sum of 2 quarters · filed 2021-03-09 | $7.61M derived: sum of 3 quarters · filed 2021-03-09 | $4.51M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$4.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$9.81M derived: sum of 2 quarters · filed 2020-11-09 | -$12.92M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | -$5.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$8.14M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | -$3.11M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $62.90M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |